Showing 1391-1400 of 1616 results for "".
- Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of Investigational Treatment for MGDhttps://modernod.com/news/azura-ophthalmics-announces-positive-topline-results-from-phase-2-program-of-the-companys-investigational-treatment-for-mgd/2478934/Azura Ophthalmics announced topline results from a phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). AZR-MD-001 met its primary endpoints showing improvements in signs and symptoms of MGD, reaching statistical significance com
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Breakthrough by Moran Eye Center Scientist, Colleagues Fuels New Line of Disease Researchhttps://modernod.com/news/breakthrough-by-moran-eye-center-scientist-colleagues-fuels-new-line-of-disease-research/2478830/Scientists like the John A. Moran Eye Center’s Paul S. Bernstein, MD, PhD, know a special class of lipids, or fatty acids, found in the retina of the eye and in just a few other parts of the body play an important role in maintaining vision. But it’s been difficult to study whether giving
- Volk Optical Releases ClearPod to Address Mask-Related Fogging During Fundus Examinationshttps://modernod.com/news/volk-optical-releases-clearpod-to-address-mask-related-fogging-during-fundus-examinations/2478724/Volk Optical announced the release their newest product, the ClearPod, which aims to solve the problem of mask-related fogging during fundus examinations. This patent-pending design has been created in collaboration with ophthalmologists Bradley Sacher, MD, a cataract specialist, and Jerem
- Samsara Vision Appoints Three New Members to the Board of Directorshttps://modernod.com/news/samsara-vision-appoints-three-new-members-to-the-board-of-directors/2478712/Samsara Vision, a developer of visual prosthetic devices for patients living with late-stage age-related macular degeneration (AMD), has announced the appointment of three new members to its Board of Directors: Jonathan H. Talamo, MD; Tracy M. Valorie; and David Schiff, joining Thierry Clidiere,
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/Azura Ophthalmics announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significan
- Kerry Solomon First in US to Implant Alcon’s Vivity IOLhttps://modernod.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/Kerry Solomon, MD, partner at Carolina Eyecare Physicians, Charleston, South Carolina, is the first in the United States following FDA approval to complete surgery using Alcon’s AcrySof IQ Vivity Extended Range of Vision IOL, according to a news release. “The Vivity lens is a remarka
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
- Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/Fight for Sight and Prevent Blindness announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elam’s study, “Engag